SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BEAM

Beam Therapeutics Inc. (NASDAQ:BEAM)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$20.90-$0.04 (-0.19%)
 
Market cap
$2.16B
Insider Score
Health Score
Analyst consensus
Listed since
Feb 6, 2020
Website
Market Cap$2.16B-11.5%
Revenue (ttm)$146.64M+163.3%
Net Income-$107.10M+74.2%
EPS-$1.04+76.6%
Shares Out103.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend DateNov 4, 2013
Volume3,882,474
Open$20.54
Previous Close$20.94
Day's Range$20.54 - $22.10
52-Week Range$20.44 - $38.26
Beta2.22
AnalystsBuy
Price Target$79.00(+277.99%)
Earnings DateFeb 23, 2027

About BEAM

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Address
238 Main Street, Cambridge, MA, 02142, US
Market Cap
2.16 billion
Employees
540
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$14.84M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy0 Hold0 SellAvg target $49.00 (+134.4%)

4 firms rating BEAM in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From BEAM’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-0.19%
5 Days
-6.74%
1 Month
-14.90%
6 Months
-27.03%
1 Year
-11.52%

$BEAM stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BEAM holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BEAM's directors and management

Net Shares Purchased by Insiders−400k−200k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BEAM Estimated quarterly lobbying spending

Source: U.S. Senate LDA

BEAM Revenue by Segment

$18.86MTotal
Stock-based compensation$18.55M98.37%
License and collaboration revenue$307.00K1.63%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New BEAM patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BEAM from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in BEAM

ARKKARK Innovation ETF$240.79M
XBIState Street SPDR S&P Biotech ETF$73.86M
VTIVanguard Morningstar Total Stock Market ETF$70.53M
VBVanguard Morningstar Small-Cap ETF$63.05M
ARKGARK Genomic Revolution ETF$60.21M
IWMiShares Russell 2000 ETF$54.41M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from BEAM’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Risto-cel met primary sickle cell trial endpoints; analyst upgrade with higher price target offsets modest stock dip from initial reaction.

Recent Insider Activity

Buys
0
Sells
16
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

+0.0 since Sep 27
0255075100Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 29.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 27Sep 30Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

TYNEDirexion Nanotechnology ETF11.13%
ARKGARK Genomic Revolution ETF4.00%
NIFEDirexion Fallen Knives ETF3.21%
ARKKARK Innovation ETF2.60%
HLTHTema Healthcare AI ETF2.21%
GNOMGlobal X - Genomics & Biotechnology ETF1.85%
WDNAWisdomTree BioRevolution Fund1.47%
TDNAT. Rowe Price Biotech ETF1.13%
MEDXHorizon Kinetics Medical ETF1.03%
XBIState Street SPDR S&P Biotech ETF0.84%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF0.84%
BBCVirtus Biotech Clinical Trials ETF0.66%

Weight is the stock’s share of each fund’s holdings.